Complete financial analysis of ShockWave Medical, Inc. (SWAV) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of ShockWave Medical, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
- VA Tech Wabag Limited (WABAG.NS) Income Statement Analysis – Financial Results
- Concord Acquisition Corp III WT (CNDB-WT) Income Statement Analysis – Financial Results
- Dominion Energy, Inc. (DCUE) Income Statement Analysis – Financial Results
- Chinese Universe Publishing and Media Group Co., Ltd. (600373.SS) Income Statement Analysis – Financial Results
- Zalando SE (ZLDSF) Income Statement Analysis – Financial Results
ShockWave Medical, Inc. (SWAV)
About ShockWave Medical, Inc.
ShockWave Medical, Inc., a medical device company, engages in developing and commercializing intravascular lithotripsy technology for the treatment of calcified plaque in patients with peripheral vascular, coronary vascular, and heart valve diseases worldwide. The company offers M5 catheters for treating above-the-knee peripheral artery disease (PAD); C2 catheters for treating coronary artery disease; and S4 catheters for treating below-the-knee PAD. It serves interventional cardiologists, vascular surgeons, and interventional radiologists through sales representatives and sales managers, and distributors. The company was incorporated in 2009 and is headquartered in Santa Clara, California.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
---|---|---|---|---|---|---|---|
Revenue | 730.23M | 489.73M | 237.15M | 67.79M | 42.93M | 12.26M | 1.72M |
Cost of Revenue | 95.39M | 65.00M | 41.44M | 20.99M | 17.16M | 7.25M | 2.84M |
Gross Profit | 634.84M | 424.74M | 195.71M | 46.80M | 25.77M | 5.01M | -1.12M |
Gross Profit Ratio | 86.94% | 86.73% | 82.53% | 69.03% | 60.03% | 40.88% | -64.98% |
Research & Development | 145.65M | 81.68M | 50.54M | 36.93M | 32.85M | 22.70M | 17.96M |
General & Administrative | 95.27M | 56.93M | 34.75M | 23.86M | 14.13M | 5.98M | 5.42M |
Selling & Marketing | 234.84M | 162.00M | 111.29M | 51.67M | 30.62M | 17.54M | 6.36M |
SG&A | 323.20M | 218.92M | 146.04M | 75.54M | 44.75M | 23.52M | 11.79M |
Other Expenses | 23.96M | 1.06M | -582.00K | 1.26M | 2.35M | 589.00K | 366.00K |
Operating Expenses | 468.85M | 300.60M | 196.58M | 112.46M | 77.61M | 46.21M | 29.75M |
Cost & Expenses | 564.24M | 365.60M | 238.02M | 133.45M | 94.77M | 53.46M | 32.58M |
Interest Income | 0.00 | 1.89M | 1.10M | 1.21M | 944.00K | 0.00 | 0.00 |
Interest Expense | 6.20M | 1.89M | 1.10M | 1.21M | 944.00K | 401.00K | 58.00K |
Depreciation & Amortization | 10.36M | -1.42M | -6.87M | 1.26M | 2.35M | 700.00K | 468.00K |
EBITDA | 176.35M | 127.57M | -871.00K | -62.32M | -49.56M | -39.91M | -30.03M |
EBITDA Ratio | 24.15% | 25.06% | -3.26% | -95.01% | -115.30% | -325.46% | -1,747.00% |
Operating Income | 165.99M | 124.13M | -871.00K | -65.66M | -51.84M | -41.20M | -30.87M |
Operating Income Ratio | 22.73% | 25.35% | -0.37% | -96.86% | -120.76% | -335.97% | -1,795.52% |
Total Other Income/Expenses | 8.29M | -3.31M | -7.96M | 44.00K | 792.00K | 136.00K | 276.00K |
Income Before Tax | 174.28M | 120.83M | -8.84M | -65.62M | -51.05M | -41.06M | -30.59M |
Income Before Tax Ratio | 23.87% | 24.67% | -3.73% | -96.80% | -118.92% | -334.86% | -1,779.46% |
Income Tax Expense | 27.00M | -95.17M | 301.00K | 80.00K | 62.00K | 38.00K | 26.00K |
Net Income | 147.28M | 216.00M | -9.14M | -65.70M | -51.11M | -41.10M | -30.62M |
Net Income Ratio | 20.17% | 44.10% | -3.85% | -96.92% | -119.06% | -335.17% | -1,780.98% |
EPS | 4.01 | 6.02 | -0.26 | -1.99 | -2.14 | -1.53 | -1.57 |
EPS Diluted | 3.85 | 5.70 | -0.26 | -1.99 | -2.14 | -1.53 | -1.57 |
Weighted Avg Shares Out | 36.71M | 35.90M | 35.10M | 33.09M | 23.90M | 26.91M | 19.53M |
Weighted Avg Shares Out (Dil) | 38.21M | 37.88M | 35.10M | 33.09M | 23.90M | 26.91M | 19.53M |
What Makes Shockwave Medical (SWAV) a Strong Momentum Stock: Buy Now?
General Motors, Celsius Lead Five Non-AI Stocks Near Buy Points
Shockwave Medical (SWAV) Q4 Earnings Beat, Revenues Rise Y/Y
Shockwave Medical, Inc. (SWAV) Q4 2023 Earnings Call Transcript
Shockwave Medical (SWAV) Surpasses Q4 Earnings and Revenue Estimates
Shockwave Medical Reports Fourth Quarter and Full Year 2023 Financial Results
Shockwave Medical Appoints Renee Gaeta as Chief Financial Officer
Shockwave Medical (SWAV) Surges 7.8%: Is This an Indication of Further Gains?
Shockwave Medical Provides Quarterly Earnings Release Dates for 2024
Reasons to Retain ShockWave Medical (SWAV) in Your Portfolio Now
Source: https://incomestatements.info
Category: Stock Reports